Adma Biologics's - ADMA market analysis on 29th September 2020

Transaction Date	Recipient	Shares	Type	Price	Value
22nd September 2020	Advisors Llc Perceptive	1,644,785	Conversion of derivative	$0.00
22nd September 2020	Advisors Llc Perceptive	1,058,824	Open or private purchase	$17.00	$18,000,008.00
15th September 2020	Advisors Llc Perceptive	2,911,764	Open or private purchase	$4.25	$12,374,997.00
14th September 2020	Advisors Llc Perceptive	1,800,000	Open or private purchase	$11.00	$19,800,000.00
14th September 2020	Advisors Llc Perceptive	400,000	Open or private purchase	$40.00	$16,000,000.00
11th September 2020	Martha J Demski	2,200	Open or private purchase	$2.29	$5,038.00
10th September 2020	Advisors Llc Perceptive	200,000	Open or private purchase	$11.24	$2,248,000.00
10th September 2020	Jerrold B Grossman	5,000	Open or private purchase	$2.22	$11,100.00
8th September 2020	Adam S Grossman	4,000	Open or private purchase	$2.24	$8,959.60
8th September 2020	James Mond	4,000	Open or private purchase	$2.20	$8,800.00

Adma Biologics

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 0/10.

ADMA Biologics, Inc. operates as a biopharmaceutical company. It develops, manufactures, and intends to commercialize in human plasma and plasma-derived therapeutics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center and Corporate.

Ticker: ADMA

Sector: Healthcare

Industry: Biotechnology

SEC Central Index Key (CIK): 1368514

Employees: 318

Exchange: NASDAQ

Auditor Opinion:

You must Login to see Language Changes

Disclosure Language changes

Analysis of subtle changes in disclosure language. Red is a sign of more constrained, less positive language changes etc. Green is more positive, less constrained etc.

You must Login to see analysis